Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
When it comes to Arena Pharmaceuticals ( ARNA ), the most popular topic of discussion is the anti-obesity drug Belviq. The drug garnered U.S. approval in June of 2012 and launched in the U.S. In June of ...
How poorly did Lexicon, Orexigen, and Ariad stocks perform this week? Bad enough to be the three worst health-care stocks in the land.
The showdown between Arena Pharmaceuticals and VIVUS in 2013 was much ado about nothing. Will Orexigen entering the obesity market in 2014 change things?
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Recent studies show that new obesity drugs, manufactured by Orexigen Therapeutics, Novo Nordisk, and VIVUS, can help patients lose weight.
Vivus ( VVUS ) is the company responsible for the anti-obesity drug Qsymia. The company is marketing the drug on its own and of late sales have been pretty flat. Vivus is seeking a big pharma partner for ...
A new Gallup poll shows a disturbing trend in U.S. eating habits. Here's a look at what could be causing our poor eating habits and what needs to be done to turn this disease on its head.
On the heels of some very positive news regarding a cardiovascular study last week, Orexigen Therapeutics ( OREX ) has now announced a proposed $100 million Senior Convertible Note offering. At the time ...
BioMarin, Orexigen and Merrimack were among the biotech stocks that made headlines last week.
MOUNTAIN VIEW, Calif., Dec. 2, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that management will present an overview of the company at the following investment conference: 25th Annual ...
Pfizer and Allergan market game-changing drugs that were discovered by accident -- but how did it happen?
The holidays are a time for giving thanks, being around family, and stuffing our faces. It's also an unwelcome time of weight gain for many. Here are five companies that directly and indirectly could help people shed some pounds following the holiday season.
A major supplier for Apple, a company with a critical anti-obesity safety study, and a potential diamond-in-the-rough company are this week's must-watch stocks.